FoRx Therapeutics
FoRx Therapeutics is a clinical-stage biotechnology company that develops precision therapeutics targeting DNA replication stress and DNA damage response pathways. The company focuses on small molecule drug discovery to treat treatment-resistant cancers. Its lead candidate, FORX-428, is a PARG inhibitor currently undergoing first-in-human clinical trials.
Biotechnology
Oncology
Pharmaceuticals
Healthcare
Funding summary
- Total raised
- €52.7M
- Funding rounds
- 2
Investors in FoRx Therapeutics
Investors on record for FoRx Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like FoRx Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors